Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study-Reference-Cited by-同舟云学术

Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study

Published:2016-05-02 Issue:8 Volume:63 Page:1407-1413
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Neunert Cindy¹,Despotovic Jenny²,Haley Kristina³,Lambert Michele P.⁴,Nottage Kerri⁵,Shimano Kristin⁶,Bennett Carolyn⁷,Klaassen Robert⁸,Stine Kimo⁹,Thompson Alexis¹⁰,Pastore Yves¹¹,Brown Travis¹²,Forbes Peter W.¹³,Grace Rachael F.¹²,

Affiliation:

1. Division of Pediatric Hematology/Oncology/Stem Cell Transplantation and New York Presbyterian Morgan Stanley Children's Hospital; Columbia University Medical Center; New York New York

2. Texas Children's Hematology Center; Baylor College of Medicine; Houston Texas

3. Division of Pediatric Hematology/Oncology; Oregon Health and Sciences University; Portland Oregon

4. Department of Pediatrics and The Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania; Philadelphia Pennsylvania

5. St. Jude Children's Research Hospital; Memphis Tennessee

6. Division of Pediatric Hematology/Oncology and Benioff Children's Hospital; University of California San Francisco; San Francisco California

7. Aflac Cancer Center and Blood Disorders Service; Emory University School of Medicine and Children's Healthcare of Atlanta; Atlanta Georgia

8. Division of Pediatric Hematology/Oncology; University of Ottawa; Ottawa Ontario

9. Division of Pediatric Hematology/Oncology; University of Arkansas for Medical Sciences at Arkansas Children's Hospital; Little Rock Arkansas

10. Division of Hematology/Oncology, Feinberg School of Medicine; Ann and Robert H. Lurie Children's Hospital of Chicago; Chicago Illinois

11. CHU Ste-Justine; Montreal University; Montreal Quebec Canada

12. Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Boston Massachusetts

13. Clinical Research Center; Boston Children's Hospital; Boston Massachusetts

Funder

Terrana Fund for ITP Research (Boston Children's Hospital)

National Institutes of Health

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference36 articles.

1. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia;Neunert;Blood,2011

2. International consensus report on the investigation and management of primary immune thrombocytopenia;Provan;Blood,2010

3. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production;Chang;Blood,1996

4. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro;Chang;Blood,2003

5. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia;Bussel;Blood,2011

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experience with Pediatric Chronic Immune Thrombocytopenia over 30 Years in the Era before Eltrombopag;Children;2024-08-28

2. Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics;Hämostaseologie;2024-06-26

3. Real-world experience of thrombopoietin receptor agonists in pediatric immune thrombocytopenia: a report from a Chinese tertiary children’s hospital;Translational Pediatrics;2024-06

4. Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2‐month‐old infant;Pediatric Blood & Cancer;2024-03-22

5. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI);Journal of Clinical Medicine;2023-10-10